Skip to main content
. 2016 Nov 8;5(12):e1255393. doi: 10.1080/2162402X.2016.1255393

Figure 2.

Figure 2.

Effect of standard of care therapies for advance pulmonary adenocarcinoma on lymphoid and myeloid cell populations. Peripheral blood of 18 pulmonary adenocarcinoma patients was analyzed for lymphoid and myeloid cell composition (depicted as percentages of the CD45+ gate) as well as changes in monocyte/macrophage (CD14+ CD11b+) and dendritic cell (CD11b−CD14−CD11c+CD206−CD163−) frequency. This was done prior to treatment (baseline) and at least 14 d after cessation of therapy (post therapy). Three treatment groups were assessed: carboplatin-vinorelbine (A, n = 5), carboplatin-pemetrexed (B, n = 7) and radiotherapy (C, n = 6). Healthy donor PBMC were taken along for comparison. The fold change of post therapy from baseline is given for the patients concerning the monocyte/macrophage and dendritic cell frequencies. Data is shown as mean with SD and Mann–Whitney U test (healthy controls compare with patients at baseline) and Wilcoxon signed rank test (patients at baseline compare with post therapy) were used for statistical analysis (***p <0.001, **p < 0.01, *p < 0.05, NS = non-significant).